All In Biotech

Investigational drug · Phase 2

Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

6

Any phase or sponsor naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab"

First trial start

2024

Sep 26, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage III
  • Non-small Cell Lung Cancer Stage IV
  • Non-small Cell Lung Cancer Recurrent

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Non-squamous Non-small-cell Lung Cancer

  • Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials

    Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer

  • JAB-3312Phase 32 trials

    Allist Pharmaceuticals, Inc. · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.